Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

AKLI Akili Inc

0,4055

-0,0145 (-3,45%)

Zuletzt aktualisiert: 21:21:17

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Akili (NASDAQ:AKLI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Akili Charts.

Akili (NASDAQ:AKLI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Akili Charts.

News Akili Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 14 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 14 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Akili Reports First Quarter 2024 Financial Results and Provides Business Update
Dienstag 14 Mai 2024 (1 Woche vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Montag 6 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Dienstag 30 April 2024 (3 Wochen vor) • Business Wire

Form ARS - Annual Report to Security Holders
Mittwoch 6 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mittwoch 6 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Mittwoch 6 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Donnerstag 29 Februar 2024 (3 Monate vor) • Business Wire

PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Dienstag 27 Februar 2024 (3 Monate vor) • Business Wire

Form 8-K - Current report
Montag 26 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Montag 26 Februar 2024 (3 Monate vor) • Business Wire

Weitere Akili Inc News-Artikel

Sterling vs JOD

NLBNPIT1S2D1 20240621 300

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen